Research Highlight Published: Osteoarthritis Nature Aging volume 5 , page 11 (2025) Cite this article 835 Accesses 5 Altmetric Metrics details Subjects In this study, the team of researchers report the results of the STEP 9 trial (NCT05064735), a 68-week, multicenter, double-blind, randomized, placebo-controlled trial to evaluate the effectiveness of subcutaneous administration of the glucagon-like peptide 1 receptor agonist semaglutide (2.4 mg) in 407 participants with obesity (body-mass index of 30) who were also clinically diagnosed with moderate knee osteoarthritis and moderate-to-severe pain, from 61 sites across 11 countries
For food intolerances or sensitivities, the issue lies in the digestive systems inability to properly break down certain foods, often due to a lack of specific enzymes
Could twins make it harder for a test to detect pregnancy
doi: 10.1016/j.diabet.2017.05.009 33
Although GLP-1RAs are well established for treating obesity, type 2 diabetes, and for reducing cardiovascular risk, their potential role in inflammatory diseases such as RA has not been clearly defined